Pillar guide to cognitive enhancement research peptides — Semax, Selank, DSIP, VIP, Oxytocin — covering BDNF, GABA, and neuroplasticity mechanisms in 2024–2026 literature.
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at 48 weeks (12 mg).
GHK-Cu copper peptide research deep dive — transcriptional mechanism, collagen synthesis, IV/SC route research, and 2024–2026 anti-aging publications.
Pillar guide to anti-aging research peptides — GHK-Cu, BPC-157, MOTS-C, SS-31, SLU-PP-332 — covering 2024–2026 mechanism data across the hallmarks of aging.
Mechanism + research review of the CJC-1295 DAC + Ipamorelin combination — dual-receptor GHRH/GHRP synergy, pulsatility preservation, and protocol design notes.
Four-peptide tissue-repair stack research review. Complementary mechanisms across inflammation, cell migration, angiogenesis, and collagen remodeling phases.
Side-by-side comparison of CJC-1295 (DAC-modified GHRH) and Sermorelin (native GHRH 1-29) — pharmacokinetics, pulsatility, stacking, and research applications.
Side-by-side comparison of tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple) — efficacy, mechanism, safety, and research selection criteria.
Independent re-testing documented ~47% retatrutide failure rates across the 2025–2026 market. How to verify your batch and what real third-party testing requires.
Pillar guide to weight loss research peptides — tirzepatide, retatrutide, cagrilintide, AOD-9604, 5-Amino-1MQ — with 2024-2026 trial data and comparative mechanisms.